Condition (MeSH)
Renal Aminoacidurias
ClinicalTrials.gov lists 21 trials for Renal Aminoacidurias or a narrower condition beneath it. Advicenne Pharma has the most among industry and government lead sponsors, with 2.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
1 of the 21 trials are tagged with Renal Aminoacidurias itself; the rest are tagged with a narrower condition beneath it.
When did Renal Aminoacidurias trials start? (13)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1/2
- Phase 2
- Phase 2/3
- Phase 4
- Not applicable
- Observational
Top of scale: 3
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2024 | 2 |
| 2023 | 1 |
| 2021 | 2 |
| 2018 | 2 |
| 2017 | 3 |
| 2016 | 2 |
| 2015 | 1 |
| 2013 | 2 |
| 2012 | 2 |
| 2009 | 1 |
Showing 10 of 13 earlier years.
No forecast is made for this condition: it averages 0.6 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: 1 trial still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Renal Aminoacidurias trials in? (6)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1/2 | 1 |
| Phase 2 | 5 |
| Phase 2/3 | 2 |
| Phase 4 | 1 |
| Not applicable | 3 |
| Observational | 9 |
How many Renal Aminoacidurias trials are recruiting? (5)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Recruiting | 5 |
| Active, not recruiting | 1 |
| Completed | 10 |
| Withdrawn | 3 |
| Unknown status | 2 |
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Renal Aminoacidurias trials? (3)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Advicenne Pharma | 2 |
| Devicare S.L. | 1 |
| Revive Therapeutics, Ltd. | 1 |
Which drugs are being tested for Renal Aminoacidurias? (3)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| BMS-512148 | 2 |
| Tiopronin | 1 |
| Bucillamine | 1 |
Interventions as named in the registry (7)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| ADV7103 | 2 |
| Tiopronin 2g per day | 1 |
| Tiopronin 1g per day | 1 |
| Tiopronin 3g per day | 1 |
| Tolvaptan IR | 1 |
Showing 5 of 7 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which publications cover Renal Aminoacidurias? (1)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Effect of hydrochlorothiazide on urinary calcium excretion in dent disease: an uncontrolled trial. | American journal of kidney diseases : the official journal of the National Kidney Foundation | 2008 | Yes |
Sub-conditions in MeSH (1)
MeSH descendants one level down with at least one trial, most trials first.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: serious adverse events in this condition's trials, prevalence, and rare-disease identity.